These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33440275)

  • 1. PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study.
    Heo YJ; Kim B; Kim H; Kim S; Jang MS; Kim KM
    Pathol Res Pract; 2021 Feb; 218():153338. PubMed ID: 33440275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy.
    Ahn S; Kim KM
    Mod Pathol; 2021 Sep; 34(9):1719-1727. PubMed ID: 34002009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of PD-L1 immunohistochemical assays in advanced gastric adenocarcinomas using endoscopic biopsy and paired resected specimens.
    Kim SW; Jeong G; Ryu MH; Park YS
    Pathology; 2021 Aug; 53(5):586-594. PubMed ID: 33546812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digital image analysis in pathologist-selected regions of interest predicts survival more accurately than whole-slide analysis: a direct comparison study in 153 gastric carcinomas.
    Heo YJ; Lee T; Byeon SJ; Kim EJ; Shin HC; Kim B; Kang SY; Ha SY; Kim KM
    J Pathol Clin Res; 2021 Jan; 7(1):42-51. PubMed ID: 32885920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.
    Kim HN; Jang J; Heo YJ; Kim B; Jung H; Jang Y; Kang SY; Kim ST; Lee J; Kang WK; Kim KM
    Virchows Arch; 2020 Feb; 476(2):243-250. PubMed ID: 31463730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.
    Zajac M; Scott M; Ratcliffe M; Scorer P; Barker C; Al-Masri H; Rebelatto MC; Walker J
    Diagn Pathol; 2019 Sep; 14(1):99. PubMed ID: 31477145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs.
    Park Y; Koh J; Na HY; Kwak Y; Lee KW; Ahn SH; Park DJ; Kim HH; Lee HS
    Cancer Res Treat; 2020 Jul; 52(3):661-670. PubMed ID: 32019283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.
    Robert ME; Rüschoff J; Jasani B; Graham RP; Badve SS; Rodriguez-Justo M; Kodach LL; Srivastava A; Wang HL; Tang LH; Troncone G; Rojo F; Van Treeck BJ; Pratt J; Shnitsa I; Kumar G; Karasarides M; Anders RA
    Mod Pathol; 2023 May; 36(5):100154. PubMed ID: 36925069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens.
    Noske A; Steiger K; Ballke S; Kiechle M; Oettler D; Roth W; Weichert W
    J Clin Pathol; 2024 Mar; 77(4):239-245. PubMed ID: 36669878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.
    Savic S; Berezowska S; Eppenberger-Castori S; Cathomas G; Diebold J; Fleischmann A; Jochum W; Komminoth P; McKee T; Letovanec I; Jasarevic Z; Rössle M; Singer G; von Gunten M; Zettl A; Zweifel R; Soltermann A; Bubendorf L
    Virchows Arch; 2019 Jul; 475(1):67-76. PubMed ID: 31127385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
    PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
    Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
    Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
    Vainer G; Huang L; Emancipator K; Nuti S
    PLoS One; 2023; 18(6):e0285764. PubMed ID: 37267266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate.
    Kim JM; Kim B; Kim E; Jang M; Cho JH; Lee HS; Kwak Y; Huang L; Krishnan R; Bai SY; Mounawar M; Kim KM
    Mol Diagn Ther; 2022 Nov; 26(6):679-688. PubMed ID: 36125657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
    Lou SK; Ko HM; Kinoshita T; MacDonald S; Weiss J; Czarnecka-Kujawa K; Boerner SL; Yasufuku K; Tsao MS; Schwock J
    Acta Cytol; 2020; 64(6):577-587. PubMed ID: 32599583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer.
    Hwang DM; Albaqer T; Santiago RC; Weiss J; Tanguay J; Cabanero M; Leung Y; Pal P; Khan Z; Lau SCM; Sacher A; Torlakovic E; Cheung C; Tsao MS
    J Thorac Oncol; 2021 Sep; 16(9):1490-1500. PubMed ID: 33915250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
    Widmaier M; Wiestler T; Walker J; Barker C; Scott ML; Sekhavati F; Budco A; Schneider K; Segerer FJ; Steele K; Rebelatto MC
    Mod Pathol; 2020 Mar; 33(3):380-390. PubMed ID: 31527709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.